| Autor: |
Naganuma K; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Takahashi Y; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Anan T; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.; Department of Transfusion and Cell Therapy, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Kizaki M; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Momose S; Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Higashi M; Department of Pathology, Saitama Medical Center, Saitama Medical University, Saitama, Japan., Tabayashi T; Department of Hematology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. |
| Abstrakt: |
High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/ASCT) has been useful in relapsed or refractory classic Hodgkin lymphoma (RRcHL). Furthermore, a ranimustine, cytarabine, etoposide, and cyclophosphamide (MCVAC) conditioning regimen has been effective in diffuse large B-cell lymphoma. However, limited data are available regarding this conditioning regimen for cHL. In this study, we investigated the efficacy and toxicity of MCVAC for RRcHL. We retrospectively analyzed 10 patients with RRcHL who underwent ASCT preceded by the MCVAC conditioning regimen between January 2009 and December 2021 at our institution. A total of 10 patients (median [range] age, 36 [23-64] years), including 5 (50%) men and 5 (50%) women, were treated with the MCVAC regimen followed by ASCT. The median follow-up duration of the 10 patients was 25.0 months. The 36-month PFS and OS rates were 43.8% (95% CI, 11.9%-72.6%) and 64.0% (95% CI, 22.6%-87.5%), respectively. Two patients died because of treatment-related factors, and one patient died because of disease progression. Based on our findings, recognizing the risk factors for adverse events (AEs) associated with this treatment, MCVAC may be a valid treatment option for the management of RRcHL. |
